drugset / Trial / NCT04876456
A Phase II Trial of Cabozantinib With Patients With Refractory GCTs
Phase 2
Active not recruiting
50 enrolled
Jennifer King
Exelixis · collabJDS Foundation Testis Cancer Clinical Trials Support Fund · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the CTO-IUSCCC-0752 study is to investigate the use of Cabozantinib for patients with incurable, refractory germ cell tumors. Patients will be treated until evidence of disease progression, non-compliance with study protocol, unacceptable major toxicity, at subject's own request for withdrawal, or if the study closes for any reason.
Timeline
- Start
- 2021-06-10
- Primary completion
- 2027-01
- Completion
- 2027-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | 60 mg | Oral |